Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type advanced or metastatic NSCLC.
Full description
Patients will be randomized in a 1:1 to receive treatment with durvalumab + tremelimumab combination therapy or SoC therapy. The primary objective of this study is to assess the efficacy of combination treatment compared with SoC in terms of Overall Survival (OS) in patients.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
For inclusion in the study, patients should fulfill the following criteria:
Exclusion criteria
Patients should not enter the study if any of the following exclusion criteria are fulfilled:
Primary purpose
Allocation
Interventional model
Masking
953 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal